insulin drugs glp 1 receptor agaonist market GLP-1 Agonists Exclusive Research Report 2025 GLP-1 Receptor Agonist Market Size,

Challenges and management of liver cirrhosis: Practical issues in the therapy of patients with cirrhosis due to NAFLD and NASH

While these findings are preliminary, they highlight the broad pharmacological potential of GLP-1based therapies and the need for continued investigation across multiple fields of medicine

Richards P, Parker HE, Adriaenssens AE, et al

Upper/Lower Gastrointestinal Symptoms Adverse event reporting databases, RCTs, and real-world data consistently show that GLP-1 RAs are commonly associated with GI symptoms such as nausea, vomiting, diarrhea, constipation, abdominal pain, and dyspeptic complaints

While this study did not investigate effectiveness for either medication, its safety profile warrants careful consideration

Piening A, Ebert E, Gottlieb C, Khojandi N, Kuehm LM, Hoft SG, et al